Keros Therapeutics
KROS
88 hedge funds and large institutions have $545M invested in Keros Therapeutics in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 28 reducing their positions, and 9 closing their positions.
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
10% more funds holding
Funds holding: 80 → 88 (+8)
1.5% less ownership
Funds ownership: 60.62% → 59.12% (-1.5%)
9% less capital invested
Capital invested by funds: $600M → $545M (-$54.6M)
11% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 28
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$6.68M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$6.16M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.75M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.57M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$5.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$37.7M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$18.2M |
| 3 |
VA
VR Adviser
New York
|
-$11.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.04M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$4.42M |
KROS Hedge Fund Activity: Q3 2021 in Review
88 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q3 2021, worth a combined $545M — down 9.1% from $600M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KROS positions and 9 closed out — a net gain of 8 holders — while 25 added to existing stakes and 28 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $6.68M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $37.7M sold.
- 88 institutional investors held Keros Therapeutics (KROS) as of Q3 2021, up from 80 in Q2 2021.
- Funds reported $545M of Keros Therapeutics stock for Q3 2021, down 9.1% quarter-over-quarter.
- 17 funds opened new Keros Therapeutics positions in Q3 2021 and 9 closed out, a net change of +8 holders.
- The largest Keros Therapeutics buyer in Q3 2021 was Woodline Partners, an estimated $6.68M added.
- The largest Keros Therapeutics seller in Q3 2021 was Consonance Capital Management, an estimated $37.7M sold.
Based on aggregated 13F filings for Q3 2021.